Glaxo

Glaxo. Originally a small trading company founded in the late 19th century, it evolved into one of the world's largest and most influential pharmaceutical and biotechnology corporations. Through a series of strategic mergers, including the landmark union with SmithKline Beecham, the company established a vast portfolio spanning prescription medicines, vaccines, and consumer health products. Its global operations and significant investments in R&D have positioned it as a critical player in addressing major public health challenges, from infectious diseases to chronic conditions, though its history has also been marked by significant legal and ethical controversies.

History

The company's origins trace back to 1873 when Joseph Nathan, a New Zealand-born entrepreneur, established Joseph Nathan and Co. as an import-export business in London. Initially dealing in dried milk and other commodities, the firm adopted the brand name "Glaxo" from a dried milk product in 1906. A pivotal shift toward pharmaceuticals began in the 1920s under the leadership of Harry Jephcott, who spearheaded the production of vitamin D and other fine chemicals, leading to the formal incorporation of **Glaxo Laboratories** in 1935. Post-World War II, the company expanded rapidly, establishing significant operations in the United Kingdom, India, and other Commonwealth nations. Its modern form was cemented through major mergers, first with Allen & Hanburys in 1958, and most notably, the 2000 creation of GlaxoSmithKline (GSK) via a union with SmithKline Beecham, itself a product of the earlier merger between SmithKline Beckman and the Beecham Group. In 2022, the company demerged its consumer healthcare division into a separate entity, Haleon.

Products and operations

The corporation maintains a diversified portfolio operating across three primary global businesses: pharmaceuticals, vaccines, and a separate consumer health entity. Its pharmaceutical division develops and markets therapies for a wide range of conditions, including HIV, asthma, COPD, and cancer, with notable drugs such as Advair and Tivicay. The vaccines unit is one of the world's largest, producing immunizations for diseases like hepatitis, rotavirus, and HPV, and it played a central role in developing a vaccine for the COVID-19 pandemic in partnership with Sanofi. Geographically, its commercial operations span over 150 countries, with major research and manufacturing sites in the United States, Belgium, and Singapore. The demerged Haleon now manages iconic over-the-counter brands including Sensodyne, Panadol, and Centrum.

Corporate affairs

Headquartered in Brentford, London, the company is a constituent of the FTSE 100 Index and is listed on the London Stock Exchange with a secondary listing on the New York Stock Exchange. Its governance is led by a Board of directors chaired by Jonathan Symonds, with Emma Walmsley serving as Chief Executive Officer. The corporate structure has undergone significant simplification, notably with the aforementioned demerger of Haleon, allowing a sharper focus on biopharmaceutical innovation. The firm engages in extensive public-private partnerships, such as those with the World Health Organization and the Bill & Melinda Gates Foundation, to improve access to medicines in the developing world. Its global workforce of approximately 70,000 is organized across international business units and dedicated research centers.

Research and development

The company's strategy is heavily driven by investment in R&D, with an annual expenditure typically exceeding £5 billion. Its science is centered on four core therapeutic areas: infectious diseases, HIV, oncology, and immunology. Key R&D facilities are located at sites like Stevenage in the UK and the Upper Providence campus in Pennsylvania. The pipeline emphasizes both small molecule drugs and biopharmaceuticals, including promising candidates in cell therapy and genetic medicine. Collaborations with academic institutions, such as the University of Cambridge, and biotechnology firms are fundamental to its innovation model. Recent significant approvals include products for RSV prevention and novel myeloma treatments, reflecting a successful translation of research.

Controversies and legal issues

The corporation has faced numerous high-profile legal challenges and settlements, particularly in the United States. In 2012, it pleaded guilty to federal charges and paid a then-record $3 billion settlement to the U.S. Department of Justice for unlawful promotion of certain drugs and failure to report safety data. It has also been involved in extensive litigation concerning its promoted use of the antidepressant Paxil and allegations surrounding the diabetes drug Avandia. In 2020, it settled a long-running bribery investigation by the U.S. Securities and Exchange Commission and the UK Serious Fraud Office over practices in China. Furthermore, the company has faced public scrutiny and patent disputes related to drug pricing and access to its HIV medications in lower-income countries. These episodes have significantly impacted its public reputation and prompted major reforms to its global compliance and marketing practices.

Category:Pharmaceutical companies of the United Kingdom Category:Companies listed on the London Stock Exchange Category:FTSE 100 Index